Category: News

ONL Therapeutics to Present at EYENOVATE and the FLORetina–ICOOR Congress 2025 ANN ARBOR, Mich., Nov. 10, 2025 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will deliver podium presentations at EYENOVATE and the FLORetina-ICOOR Congress 2025. This is…

ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD Approvals received from World Health Organization and United States Adopted Names Council establishing “xelafaslatide” as nonproprietary name for ONL1204 Ophthalmic Solution ANN ARBOR, Mich., Oct. 28, 2025 – ONL…

ONL Therapeutics Announces Multiple Presentations at Leading Ophthalmology Meetings ANN ARBOR, Mich., Feb. 4, 2025 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will present clinical data and scientific research at the following first quarter meetings: Details of…

ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing Funds will advance the development of ONL1204 Ophthalmic Solution with the initiation of a Phase 2 global study for the treatment of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) ANN ARBOR, Mich., September 13, 2024 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical…

ONL Therapeutics To Present At 2024 BIO CEO & Investor Conference ANN ARBOR, Mich., February 6, 2024 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced today that David Esposito, president and chief executive officer, will present a corporate update at the BIO CEO & Investor…

ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society  The presentation will review study population data from ONL’s Phase 2 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment  ANN ARBOR, Mich., January 23, 2024 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company…

More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 Ophthalmic Solution as adjunct to standard-of-care surgery